Corvus Pharmaceuticals
CRVS
55 hedge funds and large institutions have $288M invested in Corvus Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 6 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
59% more capital invested
Capital invested by funds: $180M → $288M (+$107M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3.87% more ownership
Funds ownership: 82.79% → 86.65% (+3.9%)
2% more funds holding
Funds holding: 54 → 55 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$14.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$11.1M |
| 5 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.83M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.12M |
| 3 |
JP Morgan Chase
New York
|
-$258K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$186K |
| 5 |
SIM
Spark Investment Management
New York
|
-$167K |
CRVS Hedge Fund Activity: Q1 2018 in Review
55 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2018, worth a combined $288M — up 59% from $180M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRVS positions and 6 closed out — a net gain of 1 holder — while 27 added to existing stakes and 10 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $16.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $4.83M sold.
- 55 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2018, up from 54 in Q4 2017.
- Funds reported $288M of Corvus Pharmaceuticals stock for Q1 2018, up 59% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q1 2018 and 6 closed out, a net change of +1 holder.
- The largest Corvus Pharmaceuticals buyer in Q1 2018 was T. Rowe Price Associates, an estimated $16.1M added.
- The largest Corvus Pharmaceuticals seller in Q1 2018 was Jennison Associates, an estimated $4.83M sold.
Based on aggregated 13F filings for Q1 2018.